Future challenges for health economics and health technology assessment of biological drugs (original) (raw)
Efectos adversos de los productos biológicos: Un metanálisis de redes y resumen cochrane
Damian Francis
Revista Médica Clínica Las Condes, 2012
View PDFchevron_right
Rheumatoid Arthritis Treatment. A Back to the Drawing Board Project or High Expectations for Low Unmet Needs?
Eleftherios Pelechas
Journal of Clinical Medicine
View PDFchevron_right
Is the outcome of rheumatoid arthritis changed with the use of new disease-modifying antirheumatic drugs?
Joel Kremer
Arthritis & Rheumatism, 2005
View PDFchevron_right
BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy
M. Lunt, M. Bukhari
Rheumatology, 2010
View PDFchevron_right
The new era of biological treatments
Doron Rimar
PubMed, 2014
View PDFchevron_right
Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis
Paul Emery
Rheumatology, 2011
View PDFchevron_right
On publication policy, combination therapy, and the European League Against Rheumatism recommendations for the management of rheumatoid arthritis: Comment on the article by Graudal et al
Simone Gorter
2011
View PDFchevron_right
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation
Olalekan Uthman
Health Technol Assess, 2011
View PDFchevron_right
Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics
Helena D'Elia
Annals of the rheumatic diseases, 2018
View PDFchevron_right
Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: Innovators, biosimilars, and intended copies
Renato Guzman
Joint Bone Spine, 2014
View PDFchevron_right
Counterpoint from the trenches: a pragmatic approach to therapeutic trials in rheumatoid arthritis
vibeke strand
Arthritis and rheumatism, 2004
View PDFchevron_right
Observational study of optimization of biologic therapies in rheumatoid arthritis: a single-centre experience
Jose Ramon Maneiro
Rheumatology International, 2013
View PDFchevron_right
Cost-utility analyses of targeted immunomodulators in rheumatoid arthritis: systematic review
Matthew Sussman
Journal of Medical Economics
View PDFchevron_right
<strong>Trends of Treatment Development in Rheumatoid Arthritis</strong><strong>: Promise, Progress, and Challenges</strong>
Steven Schrodi
2022
View PDFchevron_right
The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences
Mauro Keiserman, R. Handa
Expert Review of Clinical Immunology, 2014
View PDFchevron_right
AB0422 Cost effectiveness analysis of modified dosing regimen of biological therapy in chronic inflammatory disorder: an observational study
Anup Vishwakarma
Rheumatoid arthritis – biological DMARDs, 2018
View PDFchevron_right
Infliximab reference product versus biosimilar for the treatment of rheumatoid arthritis : scoping report
Philipp Egli
Bundesamt für Gesundheit, 2020
View PDFchevron_right
An Economic Price Analysis of Conventional Remission Therapy vs Biological Therapy for Rheumatoid Arthritis Treatment
Adina Turcu-Stiolica
DOAJ (DOAJ: Directory of Open Access Journals), 2019
View PDFchevron_right
Pharmacoeconomic evaluation of treatment effectiveness with selected biologic treatment in rheumatoid arthritis therapy
Sławomir Jeka
Reumatologia, 2018
View PDFchevron_right
Critical appraisal of pharmacoeconomic studies comparing TNF-α antagonists for rheumatoid arthritis treatment
J. Puig-junoy
Expert Review of Pharmacoeconomics & Outcomes Research, 2007
View PDFchevron_right
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
Axel Finckh
Annals of the Rheumatic Diseases, 2010
View PDFchevron_right
Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in France
Eric Boccard
Rheumatology, 2010
View PDFchevron_right
Biological therapy in rheumatoid arthritis : epidemiological studies
Katerina Chatzidionysiou
2014
View PDFchevron_right
Safety profile of biological therapies for treating rheumatoid arthritis
juan canete
Expert Opinion on Biological Therapy, 2017
View PDFchevron_right
The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis
Amanda Burls
Health technology assessment (Winchester, England), 2004
View PDFchevron_right
Biologic Treatment in Rheumatoid Arthritis
Katerina Chatzidionysiou
Autoimmune Diseases - Contributing Factors, Specific Cases of Autoimmune Diseases, and Stem Cell and Other Therapies, 2012
View PDFchevron_right